The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core.
The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core.
复制标题
DOI：
10.1016/j.jalz.2010.03.003
复制
发表时间：
2010-05
期刊：
影响因子：
--
通讯作者：
Alzheimer's Disease Neuroimaging Initiative
中科院分区：
文献类型：
--
作者：
Jagust WJ;Bandy D;Chen K;Foster NL;Landau SM;Mathis CA;Price JC;Reiman EM;Skovronsky D;Koeppe RA;Alzheimer's Disease Neuroimaging Initiative
这是阿尔茨海默病神经成像倡议(ADNI)PET核心的进展报告。核心监督了ADNI队列中大约一半的纵向[18F]氟脱氧葡萄糖PET(FDG-PET)数据的获取、质量控制和分析。在一项“附加”研究中，大约100名受试者还接受了[11C]PIB-PET扫描以进行淀粉样蛋白成像。Core开发了质量控制程序，并通过开发已在学术和制药行业研究中广泛采用的成像协议来标准化图像采集。数据处理为用户提供具有相同方向和分辨率特性的扫描，尽管在多个扫描仪型号上进行采集。Core实验室使用了许多不同的方法来表征受试组(AD、MCI、对照组)之间的差异，检查葡萄糖代谢和淀粉样蛋白沉积随时间的纵向变化，并评估FDG-PET作为临床试验中潜在结果衡量标准的使用。ADNI的数据表明，FDG-PET增加了传统认知测量的统计能力，可能有助于受试者的选择，并可以显著减少临床试验的样本量。PIB-PET数据显示了预期的组差异，并确定了受试组中淀粉样蛋白负荷每年显著增加的受试者。在ADNI中，PET核心的下一步活动将需要开发使用[18F]标记的淀粉样显像剂AV45的淀粉样成像标准化方案，该显像剂可以输送到几乎所有ADNI部位。ADNI已经证明了多中心PET研究的可行性和实用性，并正在帮助澄清生物标记物在衰老和痴呆研究中的作用。
This is a progress report of the Alzheimer's Disease Neuroimaging Initiative (ADNI) PET Core. The Core has supervised the acquisition, quality control, and analysis of longitudinal [18F]fluorodeoxyglucose PET (FDG-PET) data in approximately half of the ADNI cohort. In an “add on” study, approximately 100 subjects also underwent scanning with [11C]PIB-PET for amyloid imaging. The Core developed quality control procedures and standardized image acquisition by developing an imaging protocol that has been widely adopted in academic and pharmaceutical industry studies. Data processing provides users with scans that have identical orientation and resolution characteristics despite acquisition on multiple scanner models. The Core labs have used a number of different approaches to characterize differences between subject groups (AD, MCI, controls), to examine longitudinal change over time in glucose metabolism and amyloid deposition, and to assess the use of FDG-PET as a potential outcome measure in clinical trials. ADNI data indicate that FDG-PET increases statistical power over traditional cognitive measures, might aid subject selection, and could substantially reduce the sample size in a clinical trial. PIB-PET data showed expected group differences, and identified subjects with significant annual increases in amyloid load across the subject groups. The next activities of the PET core in ADNI will entail developing standardized protocols for amyloid imaging using the [18F]-labeled amyloid imaging agent AV45, which can be delivered to virtually all ADNI sites. ADNI has demonstrated the feasibility and utility of multicenter PET studies and is helping to clarify the role of biomarkers in the study of aging and dementia.
登录
查看更多内容
影响因子：
158.5
作者：
Reiman, EM;Caselli, RJ;Osborne, D
通讯作者：
Osborne, D
影响因子：
5.9
作者：
JACOBSON, NS;TRUAX, P
通讯作者：
TRUAX, P
影响因子：
9.9
作者：
Jagust, W. J.;Landau, S. M.;Mathis, C. A.
通讯作者：
Mathis, C. A.
影响因子：
5.7
作者：
Langbaum JB;Chen K;Lee W;Reschke C;Bandy D;Fleisher AS;Alexander GE;Foster NL;Weiner MW;Koeppe RA;Jagust WJ;Reiman EM;Alzheimer's Disease Neuroimaging Initiative
通讯作者：
Alzheimer's Disease Neuroimaging Initiative
影响因子：
--
作者：
Aizenstein, Howard Jay;Nebes, Robert D.;Saxton, Judith A.;Price, Julie C.;Mathis, Chester A.;Tsopelas, Nicholas D.;Ziolko, Scott K.;James, Jeffrey A.;Snitz, Beth E.;Houck, Patricia R.;Bi, Wenzhu;Cohen, Ann D.;Lopresti, Brian J.;DeKosky, Steven T.;Halligan, Edythe M.;Klunk, William E.
通讯作者：
Klunk, William E.